[Scleroderma].
Hasegawa
Minoru
M
Department of Dermatology, Kanazawa University Graduate School of Medical Science.
Takehara
Kazuhiko
K
Sato
Shinichi
S
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D018941:Antigens, CD19; D001323:Autoantibodies / Q000096:biosynthesis / Q000097:blood; D001402:B-Lymphocytes / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D002503:Centromere / Q000276:immunology; D003094:Collagen / Q000378:metabolism; D055513:Connective Tissue Growth Factor; D003520:Cyclophosphamide / Q000008:administration & dosage; D004264:DNA Topoisomerases, Type I / Q000276:immunology; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D011379:Prognosis; D020551:Pulse Therapy, Drug; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D016212:Transforming Growth Factor beta
D000806:Angiotensin-Converting Enzyme Inhibitors; D018941:Antigens, CD19; D001323:Autoantibodies; D015415:Biomarkers; C526317:CCN2 protein, human; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D016212:Transforming Growth Factor beta; D055513:Connective Tissue Growth Factor; D003520:Cyclophosphamide; D003094:Collagen; D004264:DNA Topoisomerases, Type I